Companies › ENCell
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EN001 Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) | – | Phase 1 | Charcot-Marie-Tooth Disease Type 1A | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06328712 | EN001 | Phase 1 | Charcot-Marie-Tooth Disease Type 1A | Neurology | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.